Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02112656 · ClinicalTrials.gov registry record · Phase 3
Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
A Phase 3 study of Hepatocellular Carcinoma, sponsored by Imunon.
- Completed
- Registry status
- Phase 3
- Development phase
- 554
- Enrollment target
- 20
- Study locations
NCT02112656: Completed Phase 3 study of Hepatocellular Carcinoma, sponsored by Imunon.
NCT02112656 is a Phase 3 study of Hepatocellular Carcinoma that has completed, run by Imunon. The registered enrollment target is 554 participants, above the 254-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (118% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02112656, a Phase 3 study of Hepatocellular Carcinoma, has completed, sponsored by Imunon.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 554 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether ThermoDox, a thermally sensitive liposomal doxorubicin, is effective in the treatment of non-resectable hepatocellular carcinoma when used in conjunction with standardized radiofrequency ablation (sRFA).
Primary Outcome
Overall survival is defined as the time (in months) from the date of randomization to the death from any cause or the end of the study.
Conditions Studied
Interventions
- DRUG ThermoDox
- DRUG Dummy infusion
Study Locations (20)
Other
- Peking University First Hospital - Beijing
- Beijing Cancer Hospital, School of Oncology, Peking - Beijing
- 302 Military Hospital of China - Beijing
- Beijing Hospital of the Ministry of Health - Beijing
- Chinese PLA General Hospital - Beijing
- West China Hospital of Sichuan University - Chengdu
- The Second Hospital of Dalian Medical University - Dalian
- Guangdong General Hospital - Guangdong
- Hunan Cancer Hospital - Hunan
- The First Hospital of Jilin University - Jilin
- Zhongshan Hospital, Fudan University - Shanghai
- The Sixth People's Hospital of Shenyang - Shenyang
- The 3rd Hospital of Tianjing - Tianjin
- The First Hospital of Zhejiang - Zhejiang
- Zhejiang Cancer Hospital - Zhejiang
- Institut für Diagnostische und Radiologische Therapie del Uniklinik Frankfurt - Frankfurt
California
- UCLA Department of Medicine - Los Angeles
Ontario
- Toronto General Hospital - Toronto
Fujian
- Mengchao Hepatobiliary Hospital of Fujian Medicatl University - Fuzhou
Shaanxi
- Xijing Hospital - Xi'an
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 554 participants |
| Start Date | 2014-06 |
| Est. Completion | 2020-04-27 |
| Phase | Phase 3 |
What the finished NCT02112656 record still lists
NCT02112656 is an interventional study that assigns participants to a tested intervention. The registered 554 participants enrollment target is mid-sized for trials with a published cap, above the 254-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (118% higher).
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which ThermoDox is the first listed.
NCT02112656 names 20 study sites across 5 states, led by Other, California, Ontario.
Frequently Asked Questions
What is clinical trial NCT02112656 about?
NCT02112656 is a clinical study titled "Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)". The purpose of this study is to determine whether ThermoDox, a thermally sensitive liposomal doxorubicin, is effective in the treatment of non-resectable hepatocellular carcinoma when used in conjunction with standardized radiofrequency ablation (sRFA).
What is the current status of trial NCT02112656?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 554 participants. The study started on 2014-06. Estimated completion is 2020-04-27.
What conditions does trial NCT02112656 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT02112656?
The interventions under investigation include: ThermoDox (DRUG), Dummy infusion (DRUG).
Who is sponsoring clinical trial NCT02112656?
This trial is sponsored by Imunon, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02112656 being conducted?
This trial has 20 study locations across California, Ontario, Fujian, Shaanxi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02112656's enrollment target sits among peer trials
554 23rd of 145 higher than 123 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
RECRUITING · Phase 3
-
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
RECRUITING · Phase 3
-
Evaluating Novel Therapies in ctDNA Positive GI Cancers
RECRUITING · Phase 3
-
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
ACTIVE NOT RECRUITING · Phase 3
-
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05786924 · 554 participants · Phase 1
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- NCT06799000 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
- NCT06840392 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
- NCT06074588 · 556 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia